Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Genentech
Deal Size : $2,300.0 million
Deal Type : Termination
Genentech Scraps $2B Cell Therapy Pact with Adaptive
Details : The companies will wind down activities under the Agreement. Upon termination, Adaptive will be released from exclusivity obligations with respect to cell therapies in oncology.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : $300.0 million
August 18, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Genentech
Deal Size : $2,300.0 million
Deal Type : Termination
Lead Product(s) : Bendamustine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Fox Chase Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
Details : Bendamustine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2024
Lead Product(s) : Bendamustine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Fox Chase Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S. Food and Drug Administration has accepted an investigational new drug (IND) application for a T-cell receptor (TCR) based T-Cell Therapy in oncology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 09, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TAK-007,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies including, TAK-007, a CD19 chimeric antigen receptor-directed cord blood derived natural k...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
April 12, 2023
Lead Product(s) : TAK-007,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Brexucabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tecartus/(KTE-X19 (brexucabtagene autoleucel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL).
Product Name : Tecartus
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 02, 2022
Lead Product(s) : Brexucabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ad26.COV2.S
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the multinational phase 3 ENSEMBLE trial, participants given Johnson & Johnson’s vaccine experienced similar efficacy against the B.1.351 variant.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 09, 2021
Lead Product(s) : Ad26.COV2.S
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Memorial Sloan Kettering Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Venetoclax is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 05, 2020
Lead Product(s) : Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Memorial Sloan Kettering Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Amgen Inc
Deal Size : Undisclosed
Deal Type : Partnership
Details : The companies will combine expertise to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 02, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Amgen Inc
Deal Size : Undisclosed
Deal Type : Partnership